Outcomes and disease evaluation
spasticity
SECONDARY, LOWER LIMB
The primary endpoint was change in walking speed (i.e. time taken) in a 10‐m walk test (10MWT) between baseline (Day 0) to Day 7. The secondary efficacy endpoints were change in walking speed in a 10MWT from baseline to Days 3 and 14; change in Timed Up and Go Test (TUGT) time from baseline to Days 3, 7, and 14; and change in cell counts, total protein level, and neopterin concentration in the cerebrospinal fluid (CSF) from baseline to Day 7. The safety of Lower limb spasticity was investigated using the Modified Ashworth Scale